GSK Bellevue mono-anti-new adaptive disorders were approved

On December 7, GlaxoSmithKline's mono-neo-adhesive disorder was approved by NMPA for use in patients 5 years of age and older who still have high disease activity (e.g., antids-DNA antibody-positive and low supplements, SELENA-SLEDAI score ≥8) on the basis of conventional treatment.
Bellevue monoantigen is a specific inhibitor of B lymphocyte stimulation factor (BLyS, also known as BAFF) belonging to first in class, which has a higher affinity with soluble BLyS in the serum, thereby blocking the binding of BLyS to the subject on the B cell, inhibiting B cell proliferation and differentiation of B cells to plasma cells, thereby reducing the self-antibodies produced by B cells in the serum for the purpose of treating SLE.
Beliyu monoantin is the only biologic agent developed by GSK in the last 60 years and the only biological agent available for the treatment of SLE in children.
was approved by the FDA in March 2011 to treat autoantibo-positive adult SLE patients, and then expanded to apply to pediatric SLE patients over 5 years of age.
, the drug was approved for sale by NMPA in July 2019.
2019 global sales of 613 million yuan, according to the Pharmaceutical Rubik's Cube PharmaGo database.
Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here